1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease.;Targan;N Engl J Med,1997
2. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn’s disease.;Rutgeerts;Gastroenterology,1997
3. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn’s disease: a multi-center, randomized, double-blind, placebo-controlled study.;Present;Am J Gastroenterol,1997
4. Infliximab for the treatment of fistulas in patients with Crohn’s disease.;Present;N Engl J Med,1999
5. Remicade™ (infliximab) Prescribing Information. 1998.